Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX®) and a tetanus monovalent vaccine in healthy adults: new considerations for the management of patients with tetanus-prone injuries.
about
Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX®) and a tetanus monovalent vaccine in healthy adults: new considerations for the management of patients with tetanus-prone injuries.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Immunogenicity and safety resu ...... s with tetanus-prone injuries.
@en
type
label
Immunogenicity and safety resu ...... s with tetanus-prone injuries.
@en
prefLabel
Immunogenicity and safety resu ...... s with tetanus-prone injuries.
@en
P2093
P2860
P356
P1476
Immunogenicity and safety resu ...... s with tetanus-prone injuries.
@en
P2093
Benoit Soubeyrand
Christine Sadorge
Florence Galtier
Henri Laurichesse
Patrick Richard
Ulrich Zimmermann
Xavier Duval
P2860
P304
P356
10.4161/HV.22083
P50
P577
2012-10-02T00:00:00Z